expert roundtables

Minimal Residual Disease Negativity in Chronic Lymphocytic Leukemia
Oncology

Minimal Residual Disease Negativity in Chronic Lymphocytic Leukemia

expert roundtables
By Anthony R. Mato, MD, MSCE; Jan A. Burger, MD, PhD; Jennifer R. Brown, MD, PhD
Oncology

Initiating Novel Agents Versus Chemoimmunotherapy in the Front-line Setting

expert roundtables
By Anthony R. Mato, MD, MSCE; Jan A. Burger, MD, PhD; Jennifer R. Brown, MD, PhD
Unmet Treatment Needs Span the Natural History of Rheumatoid Arthritis
Rheumatology

Unmet Treatment Needs Span the Natural History of Rheumatoid Arthritis

expert roundtables
By John R. P. Tesser, MD; Jonathan Kay, MD; Leonard H. Calabrese, DO; Vibeke Strand, MD, MACR, FACP
Immune Dysfunction and Infection Risk in Chronic Lymphocytic Leukemia
Oncology

Immune Dysfunction and Infection Risk in Chronic Lymphocytic Leukemia

expert roundtables
By Anthony R. Mato, MD, MSCE; Jan A. Burger, MD, PhD; Jennifer R. Brown, MD, PhD
Identifying the Role of Disease-Modifying Drugs in the Treatment of Patients With Multiple Sclerosis
Neurology

Identifying the Role of Disease-Modifying Drugs in the Treatment of Patients With Multiple Sclerosis

expert roundtables
By David A. Hafler, MD; Dean Wingerchuk, MD, FRCP(C), MSc; Staley Brod, MD
Load More